Chronic Fatigue Syndrome (CFS) represents a disabling condition characterized by persistent mental and physical fatigue, bodily discomfort and cognitive difficulties. To date the neural bases of CFS are poorly understood; however, mono-aminergic abnormalities, sleep-wake cycle changes and prefrontal dysfunctions are all thought to play a role in the development and maintenance of this condition. Here we explored in a group of 62 CFS subjects the impact on fatigue levels of agomelatine, an antidepressant with agonist activity at melatonin receptors (MT1 and MT2) and antagonist activity at serotoninergic 2C receptors (5HT2C). To tease out the relative effects of MT-agonism and 5HT2C antagonism on fatigue, we compared agomelatine 50mg u.i.d. with sustained release melatonin 10mg u.i.d. in the first 12-week-long phase of the study, and then switched all melatonin-treated subjects to agomelatine in the second 12-week-long phase of the study. Agomelatine treatment, but not melatonin, was associated with a significant reduction of perceived fatigue and an increase in perceived quality of life. Moreover the switch from melatonin to agomelatine was associated with a reduction of fatigue levels. Agomelatine was well tolerated by all enrolled subjects. Our data, albeit preliminary, suggest that agomelatine treatment could represent a novel useful approach to the clinical care of subjects with CFS.

Pardini, M., Cordano, C., Benassi, F., Mattei, C., Sassos, D., Guida, S., et al. (2014). Agomelatine but not melatonin improves fatigue perception: A longitudinal proof-of-concept study. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 24(6), 939-944 [10.1016/j.euroneuro.2014.02.010].

Agomelatine but not melatonin improves fatigue perception: A longitudinal proof-of-concept study

EMBERTI, LEONARDO
2014-01-01

Abstract

Chronic Fatigue Syndrome (CFS) represents a disabling condition characterized by persistent mental and physical fatigue, bodily discomfort and cognitive difficulties. To date the neural bases of CFS are poorly understood; however, mono-aminergic abnormalities, sleep-wake cycle changes and prefrontal dysfunctions are all thought to play a role in the development and maintenance of this condition. Here we explored in a group of 62 CFS subjects the impact on fatigue levels of agomelatine, an antidepressant with agonist activity at melatonin receptors (MT1 and MT2) and antagonist activity at serotoninergic 2C receptors (5HT2C). To tease out the relative effects of MT-agonism and 5HT2C antagonism on fatigue, we compared agomelatine 50mg u.i.d. with sustained release melatonin 10mg u.i.d. in the first 12-week-long phase of the study, and then switched all melatonin-treated subjects to agomelatine in the second 12-week-long phase of the study. Agomelatine treatment, but not melatonin, was associated with a significant reduction of perceived fatigue and an increase in perceived quality of life. Moreover the switch from melatonin to agomelatine was associated with a reduction of fatigue levels. Agomelatine was well tolerated by all enrolled subjects. Our data, albeit preliminary, suggest that agomelatine treatment could represent a novel useful approach to the clinical care of subjects with CFS.
2014
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/26 - NEUROLOGIA
English
Agomelatine; Dopamine; Fatigue; Melatonin; Noradrenaline; Acetamides; Adult; Antidepressive Agents; Fatigue; Fatigue Syndrome, Chronic; Female; Follow-Up Studies; Humans; Longitudinal Studies; Male; Melatonin; Pilot Projects; Psychiatric Status Rating Scales; Quality of Life; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Receptor, Serotonin, 5-HT2C; Serotonin 5-HT2 Receptor Antagonists; Treatment Outcome
Pardini, M., Cordano, C., Benassi, F., Mattei, C., Sassos, D., Guida, S., et al. (2014). Agomelatine but not melatonin improves fatigue perception: A longitudinal proof-of-concept study. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 24(6), 939-944 [10.1016/j.euroneuro.2014.02.010].
Pardini, M; Cordano, C; Benassi, F; Mattei, C; Sassos, D; Guida, S; Serrati, C; Primavera, A; Amore, M; Cocito, L; Emberti, L
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Emberti_Gialloreti_Agomelatine_and_Melatonine.pdf

solo utenti autorizzati

Licenza: Copyright dell'editore
Dimensione 353.25 kB
Formato Adobe PDF
353.25 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/140815
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 7
social impact